Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Rhythm · Phase 2 · Completed · Enrollment 40

NCT02311673

ArmPopulationDoseWeeksEstimandWeight change
Setmelanotide 0.5 mgPrader-Willi Syndrome0.5 mgn/rn/rn/r
Setmelanotide 1.5 mgPrader-Willi Syndrome1.5 mgn/rn/rn/r
Setmelanotide 2.5 mgPrader-Willi Syndrome2.5 mgn/rn/rn/r
PlaceboPrader-Willi Syndromen/rn/rn/rn/r